RenovoRx Publishes PK/PD Data Showing 51% Tumor-Site Drug Extraction in Pancreatic Cancer Trial
RNXT sits 93% above its 52-week low of $0.701.
Summary
RenovoRx published peer-reviewed PK/PD data from a sub-study of its Phase III TIGeR-PaC trial in Cancer Chemotherapy and Pharmacology. The data show approximately 51% of intra-arterially delivered gemcitabine was extracted at the tumor site before entering systemic circulation, with significantly lower systemic exposure compared to intravenous delivery. A statistically significant correlation between higher dFdU levels and greater CA 19-9 tumor marker reductions (r = -0.75, P = 0.034) provides an early pharmacodynamic signal of tumor response. This follows full enrollment of the TIGeR-PaC trial in August 2026 and adds mechanistic support for the TAMP platform ahead of topline data expected in the second half of 2027. The publication strengthens the scientific rationale for the company's targeted drug-delivery approach in locally advanced pancreatic cancer.
At the time of this announcement, RNXT was trading at $1.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $56.4M. The 52-week trading range was $0.70 to $1.51. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.